DAMGO (TFA)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

DAMGO (TFA)  纯度: 99.76%

DAMGO TFA 是一种选择性的 μ-阿片受体 (μ-OPR) 激动剂,Kd 值为 3.46 nM。

DAMGO (TFA)

DAMGO (TFA) Chemical Structure

CAS No. : 950492-85-0

规格 价格 是否有货 数量
10 mM * 1 mL in Water ¥1367 In-stock
1 mg ¥600 In-stock
5 mg ¥990 In-stock
10 mg ¥1700 In-stock
25 mg ¥3700 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

DAMGO (TFA) 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Neuronal Signaling Compound Library
  • Anti-Cancer Compound Library
  • Neurotransmitter Receptor Compound Library
  • Peptide Library

生物活性

DAMGO TFA is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR[1].

分子量

627.61

Formula

C28H36F3N5O8

CAS 号

950492-85-0

Sequence

Tyr-{d-Ala}-Gly-{Me-Phe}-Gly-ol

Sequence Shortening

Y-{d-Ala}-G-{Me-Phe}-G-ol

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

H2O : 125 mg/mL (199.17 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5933 mL 7.9667 mL 15.9335 mL
5 mM 0.3187 mL 1.5933 mL 3.1867 mL
10 mM 0.1593 mL 0.7967 mL 1.5933 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. FEBS Lett. 1995 Jan 2;357(1):93-7. Onogi T, et al. DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

DAMGO

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

DAMGO  纯度: 99.61%

DAMGO 是 一种选择性的 μ-阿片受体 (μ-OPR) 激动剂,Kd 值为 3.46 nM。

DAMGO

DAMGO Chemical Structure

CAS No. : 78123-71-4

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1119 In-stock
1 mg ¥600 In-stock
5 mg ¥990 In-stock
10 mg ¥1700 In-stock
25 mg ¥3700 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

DAMGO 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Neuronal Signaling Compound Library
  • Anti-Cancer Compound Library
  • Neurotransmitter Receptor Compound Library
  • Neuroprotective Compound Library
  • Peptide Library

生物活性

DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a Kd of 3.46 nM for native μ-OPR[1].

IC50 & Target

Kd: 3.46±0.84 nM (native μ-OPR)[1]

体外研究
(In Vitro)

DAMGO, a μ-opioid receptor selective agonist, distinguishes between μ- and δ-opioid receptors around their first extracellular loops. In native μ-OPR, the Kd value for DAMGO is 3.46± 0.84 nM (n=3). The chimeric receptor MMDD, in which the carboxy-terminal half of μ-OPR is replaced with the corresponding region of δ-OPR, exhibits an equivalent affinity (Kd=2.13±0.40 nM; n=3) to DAMGO compared with the native μ-OPR[1]. DAMGO is a selective μ-opioid peptide. DAMGO abolishes the neuroprotective effect of CXCL12 in N-methyl-d-aspartate (NMDA) neurotoxicity studies. Regulation of neuronal response to CXCL12 is essential for shaping of developing and mature central nervous system (CNS). To establish whether DAMGO alter the effect of CXCL12 on neuronal survival, the ability of CXCL12 to protect neurons from N-methyl-d-aspartate (NMDA)-induced death is examined in the presence and absence of DAMGO. Cortical cultures are treated with DAMGO (1 and 10 μM). Neurons are subsequently exposed to NMDA (20 min) and/or CXCL12 (added 10 min before NMDA) in the absence of glia and then returned to the original culture dishes with the glial feeder layer. Neuronal death is evaluated after 24 h. DAMGO inhibits neuronal survival promoted by CXCL12[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

513.59

Formula

C26H35N5O6

CAS 号

78123-71-4

Sequence

Tyr-{d-Ala}-Gly-{Me-Phe}-Gly-ol

Sequence Shortening

Y-{d-Ala}-G-{Me-Phe}-G-ol

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Protect from light

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO : 33.33 mg/mL (64.90 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9471 mL 9.7354 mL 19.4708 mL
5 mM 0.3894 mL 1.9471 mL 3.8942 mL
10 mM 0.1947 mL 0.9735 mL 1.9471 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.87 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.87 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.87 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. FEBS Lett. 1995 Jan 2;357(1):93-7. Onogi T, et al. DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops.

    [2]. Patel JP, et al. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol. 2006 Dec;12(6):492-500.

Cell Assay
[2]

Neurons (9 days in vitro) are treated with DAMGO (10 μM) for 24 h in their original culture dish, subsequently transferred to a dish containing Mg2+-free saline with glycine (15 μM), and exposed to NMDA (100 μM) and/or CXCL12 (20 nM) in absence of glia. After treatments, neurons are moved back into the original culture dishes containing glia. Neuronal death is evaluated after 24 h. Hoechst 33342 (3 μg/mL) combined with cleaved caspase-3 (1:100) staining is used to identify normal and apoptotic cells[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. FEBS Lett. 1995 Jan 2;357(1):93-7. Onogi T, et al. DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops.

    [2]. Patel JP, et al. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol. 2006 Dec;12(6):492-500.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务